AEROVATE THERAPEUTICS INC (AVTE)
US0080641071 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, MPB, AVTE on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, STAF, AVTE on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
The trading volume of these stocks is deviating from the norm in today's session.
The trading volume of these stocks is deviating from the norm in today's session.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Which stocks are moving before the opening bell on Thursday?
Which stocks are moving before the opening bell on Thursday?
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Noteworthy Thursday Option Activity: AVTE, BYON, DASH
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q2 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aerovate Therapeutics (NASDAQ:AVTE) just reported results for the second quarte...
Aerovate Therapeutics to Explore Strategic Alternatives
Aerovate Therapeutics to Explore Strategic Alternatives
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and...
The 3 Hottest Stock Downgrades From Last Week
Explore the experts' latest surprising stock downgrades amid significant market shifts and analyst adjustments.
Monday Sector Laggards: Paper & Forest Products, Biotechnology Stocks
Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke
The company was working on a treatment for pulmonary arterial hypertension, a form of high blood pressure in the lungs.
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses...
Notable Friday Option Activity: AVTE, FND, REI
Notable Wednesday Option Activity: AVTE, MDGL, BASE
AVTE Makes Notable Cross Below Critical Moving Average
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024...
Commit To Buy Aerovate Therapeutics At $10, Earn 171.1% Annualized Using Options
Aerovate Therapeutics Enters Oversold Territory (AVTE)
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024
AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aerovate Therapeutics (NASDAQ:AVTE) just reported results for the first quarter...
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial...